THE CORPORATE LIBRARY

Related Party Transactions and Outside Related Director Information

Wyeth (WYE)

3/15/2006 Proxy Information

The Company retained the law firm of Pepper Hamilton LLP in connection with various legal matters in 2005 and has paid or is expected to pay $277,202 for these services. In 2006, the Company has and expects to continue to retain this firm, with approximately $9,519 in net billings to date. Nina M. Gussack is a partner at Pepper Hamilton and the sister-in-law of Lawrence V. Stein, Senior Vice President and General Counsel of the Company. As part of Pepper HamiltonŐs overall representation of the Company, Ms. Gussack has provided specialized legal advice regarding clinical trial and drug development to the Company. Following Mr. SteinŐs promotion to General Counsel of the Company as of July 1, 2003, the Audit Committee of the Board of Directors established procedures for hiring Pepper Hamilton while Mr. Stein is General Counsel. Under these procedures, which require the approval of the Chief Executive Officer or Chief Financial Officer for retention, Mr. Stein is not directly involved in determinations to retain Pepper Hamilton, although as General Counsel he has a right to veto any retention which has been approved.

3/16/2005 Proxy Information

The Company retained the law firm of Pepper Hamilton LLP in connection with various legal matters in 2004 and has paid or is expected to pay $901,204 for these services. In 2005, the Company has and expects to continue to retain this firm, with approximately $55,000 in net billings to date. Nina M. Gussack is a partner at Pepper Hamilton and the sister-in-law of Lawrence V. Stein, Senior Vice President and General Counsel of the Company. As part of Pepper HamiltonŐs overall representation of the Company, Ms. Gussack has provided specialized legal advice regarding clinical trial and drug development, to the Company. Following Mr. SteinŐs promotion to General Counsel of the Company as of July 1, 2003, the Audit Committee of the Board of Directors established procedures for hiring Pepper Hamilton while Mr. Stein is General Counsel. Under these procedures, which require the approval of the Chief Executive Officer or Chief Financial Officer for retention, Mr. Stein is not directly involved in determinations to retain Pepper Hamilton, although as General Counsel he has a right to veto any retention which has been approved.

3/17/2004 Proxy Information

John R. Stafford was Chairman of Wyeth from 1986 to 2002, Chief Executive Officer from 1986 to April 2001 and President from 1981 to 1990.

From time to time, the Company has retained the law firm of Pepper Hamilton LLP in connection with various legal matters and was billed $1,370,125 for these services during 2003. Nina M. Gussack is a partner at Pepper Hamilton and the sister-in-law of Lawrence V. Stein, Senior Vice President and General Counsel of the Company. As part of Pepper HamiltonŐs overall representation of the Company, Ms. Gussack has provided specialized legal advice regarding clinical trial and drug development, to the Company. Following Mr. SteinŐs promotion to General Counsel of the Company as of July 1, 2003, the Audit Committee of the Board of Directors established procedures for hiring Pepper Hamilton while Mr. Stein is General Counsel. Under these procedures, which require the approval of the Chief Executive Officer or Chief Financial Officer for retention, Mr. Stein is not directly involved in determinations to retain Pepper Hamilton, although as General Counsel he has a right to veto any retention which has been approved.

INDEBTEDNESS OF MANAGEMENT

On April 4, 2002, the Company made a three-year loan to one of our key employees, Ulf Wiinberg, in the amount of $250,000 with interest set at the applicable short-term rate of 2.88% per annum to assist him in relocating to the United States in connection with his promotion to President of Wyeth Consumer Healthcare. This loan was made prior to the enactment of the Sarbanes-Oxley Act of 2002 which, among other things, generally disallows loans to executive officers. However, at his election, in 2003 Mr. Wiinberg fully repaid the loan early with interest.

3/18/2003 Proxy information

On April 4, 2002, we made a loan to Ulf Wiinberg in the amount of $250,000 to assist him in relocating to the United States in connection with his promotion to President of Wyeth Consumer Healthcare (he previously was not an executive officer). This loan bears interest at the applicable federal short-term rate of 2.88% per annum and is required to be repaid in three annual installments ending in March 2005. Although this loan was made prior to the enactment of the Sarbanes-Oxley Act of 2002 which, among other things, generally disallows loans to executive officers, Mr. Wiinberg has made arrangements to repay the loan in full in the near future.

On January 14, 1998, our directors (other than Messrs. Essner, Carri—n and Shipley), certain officers, a former director and officer and Wyeth (as a nominal defendant) were named in a stockholder derivative action filed in New Jersey Superior Court, Morris County (No. MRS-L-164-98). The suit seeks to recover any losses or damages sustained by Wyeth, as well as profits from the sale of stock by certain present and former officers and directors, as a result of alleged intentional, reckless or negligent breaches of fiduciary duty by the defendants. The suit alleges that the defendants made material misstatements or omissions regarding alleged adverse events associated with REDUX and/or PONDIMIN (and in particular an alleged association between those two products and valvular heart disease), exposing Wyeth to liability for personal injury lawsuits and securities claims. The defendantsŐ motion to dismiss the case has been granted and this ruling was affirmed on appeal in January 2003. The deadline for plaintiffs to petition the New Jersey Supreme Court to review the dismissal has now expired. The defendants believe that this suit is without merit and intend to continue to defend the litigation vigorously.